303 related articles for article (PubMed ID: 15616145)
1. Topotecan in the treatment of recurrent small cell lung cancer: an update.
Ardizzoni A
Oncologist; 2004; 9 Suppl 6():4-13. PubMed ID: 15616145
[TBL] [Abstract][Full Text] [Related]
2. Quality-of-life considerations in patients with advanced lung cancer: effect of topotecan on symptom palliation and quality of life.
Gralla RJ
Oncologist; 2004; 9 Suppl 6():14-24. PubMed ID: 15616146
[TBL] [Abstract][Full Text] [Related]
3. Update on the role of topotecan in the treatment of non-small cell lung cancer.
Stewart DJ
Oncologist; 2004; 9 Suppl 6():43-52. PubMed ID: 15616149
[TBL] [Abstract][Full Text] [Related]
4. Emerging role of weekly topotecan in recurrent small cell lung cancer.
Eckardt JR
Oncologist; 2004; 9 Suppl 6():25-32. PubMed ID: 15616147
[TBL] [Abstract][Full Text] [Related]
5. Topotecan in the first-line treatment of small cell lung cancer.
Stewart DJ
Oncologist; 2004; 9 Suppl 6():33-42. PubMed ID: 15616148
[TBL] [Abstract][Full Text] [Related]
6. [Effect of topotecan as a second line treatment in small cell lung cancer patients. Preliminary report].
Biernacka B; Krawczyk P; Buczkowski J; Siwiec A; Perzyło K; Milanowski J
Pneumonol Alergol Pol; 2010; 78(3):192-202. PubMed ID: 20461687
[TBL] [Abstract][Full Text] [Related]
7. Topotecan in small cell lung cancer.
Schiller JH
Semin Oncol; 1997 Dec; 24(6 Suppl 20):S20-27-S20-33. PubMed ID: 9425958
[TBL] [Abstract][Full Text] [Related]
8. Phase III study of oral compared with intravenous topotecan as second-line therapy in small-cell lung cancer.
Eckardt JR; von Pawel J; Pujol JL; Papai Z; Quoix E; Ardizzoni A; Poulin R; Preston AJ; Dane G; Ross G
J Clin Oncol; 2007 May; 25(15):2086-92. PubMed ID: 17513814
[TBL] [Abstract][Full Text] [Related]
9. Topotecan and etoposide as first-line therapy for extensive disease small cell lung cancer: a phase II trial of a platinum-free regimen.
Reck M; Groth G; Buchholz E; Goetz E; Gatzemeier U; Manegold C
Lung Cancer; 2005 Jun; 48(3):409-13. PubMed ID: 15893010
[TBL] [Abstract][Full Text] [Related]
10. Topotecan for the treatment of small-cell lung cancer.
Nicum SJ; O'Brien ME
Expert Rev Anticancer Ther; 2007 Jun; 7(6):795-801. PubMed ID: 17555389
[TBL] [Abstract][Full Text] [Related]
11. Hematologic safety and tolerability of topotecan in recurrent ovarian cancer and small cell lung cancer: an integrated analysis.
Armstrong DK; Spriggs D; Levin J; Poulin R; Lane S
Oncologist; 2005 Oct; 10(9):686-94. PubMed ID: 16249347
[TBL] [Abstract][Full Text] [Related]
12. Phase III trial comparing supportive care alone with supportive care with oral topotecan in patients with relapsed small-cell lung cancer.
O'Brien ME; Ciuleanu TE; Tsekov H; Shparyk Y; Cuceviá B; Juhasz G; Thatcher N; Ross GA; Dane GC; Crofts T
J Clin Oncol; 2006 Dec; 24(34):5441-7. PubMed ID: 17135646
[TBL] [Abstract][Full Text] [Related]
13. Effective combination chemotherapy of carboplatin and paclitaxel in the treatment of a recurrent small-cell lung cancer patient.
Kaira K; Ishizuka T; Yanagitani N; Sunaga N; Hisada T; Mori M
Gan To Kagaku Ryoho; 2007 Feb; 34(2):225-7. PubMed ID: 17301532
[TBL] [Abstract][Full Text] [Related]
14. Topotecan versus cyclophosphamide, doxorubicin, and vincristine for the treatment of recurrent small-cell lung cancer.
von Pawel J; Schiller JH; Shepherd FA; Fields SZ; Kleisbauer JP; Chrysson NG; Stewart DJ; Clark PI; Palmer MC; Depierre A; Carmichael J; Krebs JB; Ross G; Lane SR; Gralla R
J Clin Oncol; 1999 Feb; 17(2):658-67. PubMed ID: 10080612
[TBL] [Abstract][Full Text] [Related]
15. Second-line chemotherapy in recurrent small cell lung cancer. Results from a crossover schedule after primary treatment with cisplatin and etoposide (EP-regimen) or cyclophosphamide, epirubicin, and vincristin (CEV-regimen).
Sundstrøm S; Bremnes RM; Kaasa S; Aasebø U; Aamdal S;
Lung Cancer; 2005 May; 48(2):251-61. PubMed ID: 15829326
[TBL] [Abstract][Full Text] [Related]
16. Topotecan versus treosulfan, an alkylating agent, in patients with epithelial ovarian cancer and relapse within 12 months following 1st-line platinum/paclitaxel chemotherapy. A prospectively randomized phase III trial by the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group (AGO-OVAR).
Meier W; du Bois A; Reuss A; Kuhn W; Olbricht S; Gropp M; Richter B; Lück HJ; Kimmig R; Pfisterer J
Gynecol Oncol; 2009 Aug; 114(2):199-205. PubMed ID: 19446314
[TBL] [Abstract][Full Text] [Related]
17. Recent advances with topotecan in the treatment of lung cancer.
O'Brien M; Eckardt J; Ramlau R
Oncologist; 2007 Oct; 12(10):1194-204. PubMed ID: 17962613
[TBL] [Abstract][Full Text] [Related]
18. A multi-center phase II study of weekly topotecan as second-line therapy for small cell lung cancer.
Shah C; Ready N; Perry M; Kirshner J; Gajra A; Neuman N; Garziano S
Lung Cancer; 2007 Jul; 57(1):84-8. PubMed ID: 17399850
[TBL] [Abstract][Full Text] [Related]
19. New advances in the second-line treatment of small cell lung cancer.
Hurwitz JL; McCoy F; Scullin P; Fennell DA
Oncologist; 2009 Oct; 14(10):986-94. PubMed ID: 19819917
[TBL] [Abstract][Full Text] [Related]
20. Topotecan: a review of its efficacy in small cell lung cancer.
Ormrod D; Spencer CM
Drugs; 1999 Sep; 58(3):533-51. PubMed ID: 10493279
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]